Please login to the form below

Not currently logged in
Email:
Password:

AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

Joins as company prepares to advance APF350 to treat side effects of chemotherapy

Jesse Hollingsworth has left Dendreon to join AP Pharma as VP of sales.

The appointment comes as AP Pharma prepares to advance its lead product APF350, which is intended for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting.

“Over the past several months, AP Pharma has been focused on recruiting key additions to our management team, and Jesse's experience in oncology sales will provide insights into the sales progamme for ... APF350,” said Robert Rosen, AP Pharma's chief commercial officer.

This experience includes Hollingsworth's time as senior director of group purchasing organisation and trade strategy at Dendreon, which developed the prostate cancer vaccine Provenge.

Prior to this role, Hollingsworth was senior director of strategic business development and marketing at ION Solutions.

This was preceded by a period as marketing director for the oncology business unit of Amgen, where he worked on such products as Neulasta, Neupogen and Vectibix.

5th March 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....